These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20061787)

  • 1. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer.
    Mansure JJ; Nassim R; Chevalier S; Rocha J; Scarlata E; Kassouf W
    Cancer Biol Ther; 2009 Dec; 8(24):2339-47. PubMed ID: 20061787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro effects of RAD001 on bladder cancer.
    Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
    Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
    Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
    Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.
    Chiong E; Lee IL; Dadbin A; Sabichi AL; Harris L; Urbauer D; McConkey DJ; Dickstein RJ; Cheng T; Grossman HB
    Clin Cancer Res; 2011 May; 17(9):2863-73. PubMed ID: 21415218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
    Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Takaoka M; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
    Oncol Rep; 2010 Apr; 23(4):1167-72. PubMed ID: 20204306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
    Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
    Mabuchi S; Altomare DA; Connolly DC; Klein-Szanto A; Litwin S; Hoelzle MK; Hensley HH; Hamilton TC; Testa JR
    Cancer Res; 2007 Mar; 67(6):2408-13. PubMed ID: 17363557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination.
    Mordant P; Loriot Y; Leteur C; Calderaro J; Bourhis J; Wislez M; Soria JC; Deutsch E
    Mol Cancer Ther; 2010 Feb; 9(2):358-68. PubMed ID: 20124452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
    Makhlin I; Zhang J; Long CJ; Devarajan K; Zhou Y; Klein-Szanto AJ; Huang M; Chernoff J; Boorjian SA
    BJU Int; 2011 Jul; 108(2 Pt 2):E84-90. PubMed ID: 21050361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Ni L; Koeffler HP; Yokoyama A
    Exp Hematol; 2010 Aug; 38(8):666-76. PubMed ID: 20382200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells.
    Cai Y; Xia Q; Su Q; Luo R; Sun Y; Shi Y; Jiang W
    Int J Mol Med; 2013 Apr; 31(4):904-12. PubMed ID: 23426850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.
    Hansel DE; Platt E; Orloff M; Harwalker J; Sethu S; Hicks JL; De Marzo A; Steinle RE; Hsi ED; Theodorescu D; Ching CB; Eng C
    Am J Pathol; 2010 Jun; 176(6):3062-72. PubMed ID: 20395440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.
    Lin JF; Lin YC; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
    Drug Des Devel Ther; 2016; 10():1501-13. PubMed ID: 27143856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer.
    Pinto-Leite R; Arantes-Rodrigues R; Palmeira C; Colaço B; Lopes C; Colaço A; Costa C; da Silva VM; Oliveira P; Santos L
    Biomed Pharmacother; 2013 Mar; 67(2):116-21. PubMed ID: 23433853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
    Mabuchi S; Altomare DA; Cheung M; Zhang L; Poulikakos PI; Hensley HH; Schilder RJ; Ozols RF; Testa JR
    Clin Cancer Res; 2007 Jul; 13(14):4261-70. PubMed ID: 17634556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
    Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
    Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma.
    Huynh H; Chow KH; Soo KC; Toh HC; Choo SP; Foo KF; Poon D; Ngo VC; Tran E
    J Cell Mol Med; 2009 Jul; 13(7):1371-80. PubMed ID: 18466352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Synergistic effect of rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells].
    Zhang YJ; Fang JY; Sun DF; Zhao SL; Shen GF; Zheng Q; Zhu HY
    Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):889-93. PubMed ID: 18478925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.